301089.SZ
Tuoxin Pharmaceutical Group Co., Ltd.
SZSE · C 制造业 · CN
CNY 23.14
−4.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 373.9M | 378.3M | 421.7M | 835.5M | 784.7M |
| Cost of Revenue | 281.3M | 278.5M | 295.7M | 352.0M | 313.0M |
| Gross Profit | 92.6M | 99.8M | 125.9M | 483.6M | 471.7M |
| Operating Expenses | |||||
| R&D Expense | 43.0M | 42.7M | 40.0M | 51.2M | 31.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 90.9M | 94.9M | 91.5M | 94.5M | 105.6M |
| Selling & Marketing Expense | 10.2M | 10.4M | 13.0M | 9.8M | 9.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 152.6M | 156.2M | 148.9M | 165.2M | 154.4M |
| Cost and Expenses | 433.8M | 434.8M | 444.7M | 517.2M | 467.4M |
| Operating Income (EBIT) | (81.5M) | (71.8M) | (23.7M) | 321.7M | 329.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (81.9M) | (72.4M) | (27.7M) | 316.5M | 325.3M |
| Income Tax Expense | (5.3M) | (2.7M) | (7.8M) | 73.5M | 38.7M |
| Bottom Line | |||||
| Net Income | (76.6M) | (69.7M) | (19.9M) | 243.1M | 286.5M |
| Earnings from Cont. Ops | (76.6M) | (69.7M) | (19.9M) | 243.1M | 286.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (76.6M) | (69.7M) | (19.9M) | 243.1M | 286.5M |
| Per Share | |||||
| Basic EPS | (CN¥0.60) | (CN¥0.55) | (CN¥0.16) | CN¥1.93 | CN¥2.27 |
| Diluted EPS | (CN¥0.60) | (CN¥0.55) | (CN¥0.16) | CN¥1.93 | CN¥2.27 |
| Revenue Per Share | CN¥2.85 | CN¥2.99 | CN¥3.39 | CN¥6.63 | CN¥6.22 |
| Shares | |||||
| Basic Shares Outstanding | 131.4M | 126.7M | 124.3M | 125.9M | 126.2M |
| Diluted Shares Outstanding | 131.4M | 126.7M | 124.3M | 125.9M | 126.2M |
| Profitability Metrics | |||||
| EBITDA | — | (5.6M) | 24.5M | 368.8M | 370.3M |
| D&A | — | 66.2M | 48.2M | 47.1M | 41.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026